Clinical Trial Update: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating a fully human BCMA-targeting CAR T therapy (CT103A) in relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CT103A (BCMA-targeting CAR T)

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN